Skip to main content

All Publications

Khurram Nasir, Baptist Health Medical GroupFollow

Applicability and Cost Implications for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Based on the ODYSSEY Outcomes Trial

Publication Date

2019

Content Type

Article

PubMed ID:

Additional Authors:

Additional authors and institutional affiliations

Citation

Circulation (2019) 139(3):410-412

Restricted

Available to BHSF community via local IP address or BHSF login.

Find in your library

COinS